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Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social communication deficits
and repetitive behaviors. Owing to the difficulty of clinical diagnosis, ASD without intellectual disability (i.e., high-
functioning ASD) is often overlooked. MicroRNAs (miRNAs) have been recently recognized as potential biomarkers
of ASD as they are dysregulated in various tissues of individuals with ASD. However, it remains unclear whether
miRNA expression is altered in individuals with high-functioning ASD. Here, we investigated the miRNA expression
profile in peripheral blood from adults with high-functioning ASD, and age and gender-matched healthy controls.
We identified miR-6126 as being robustly down-regulated in ASD and correlated with the severity of social deficits.
Enrichment analysis of predicted target genes revealed potential association with neurons, synapses, and oxytocin
signaling pathways. Our findings may provide insights regarding the molecular clues for recognizing high-
functioning ASD.
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Autism spectrum disorder (ASD) is a neurodevelopmen-
tal disorder characterized by social communication defi-
cits and repetitive behaviors [1]. ASD diagnosis is
currently based on clinical symptoms. However, the ob-
jective and quantitative assessment of sociality can be
challenging during the limited time commonly available
in clinical appointments. Additionally, it has recently
been recognized that a substantial number of cases of
ASD are overlooked, even until adulthood [2]. This may
occur because the diagnosis of ASD is usually made in
early childhood concomitant with evident symptoms;
conversely, recognition of cases with less severe symp-
toms and/or without associated intellectual disability
(ID), such as those with average or above-average
intelligence quotients (IQ) (full-scale IQ > 70; i.e., high-
functioning ASD) is likely to be delayed. Furthermore,
these late-diagnosed individuals tend to suffer from
mental health problems related to long-term stress from
daily life [2, 3], highlighting the needed for accurate
diagnosis and adequate support.
Numerous studies have attempted to identify bio-
markers to facilitate ASD diagnosis. For example, micro-
RNAs (miRNAs), which comprise small non-coding
RNAs that participate in post-transcriptional regulation of
gene expression, constitute a potential biomarker in psy-
chiatric disorders owing to their advantage of stability [4].
Accumulating evidence supports that miRNA expression
profiles are altered in various tissues of patients with ASD
including the brain, blood, and saliva [5]. However, most
studies to date have focused on children with classic ASD;
to our knowledge, no published studies have reported
miRNA alterations in high-functioning ASD [5].
Here, we sought to explore miRNAs in the blood from
adults with high-functioning ASD. A flow chart of the
study is shown in Fig. 1a. The clinical characteristics of
participants are shown in Additional file 1: Table S1. No
participants exhibited ID although small albeit signifi-
cant differences in full and performance IQ scores were
noted between subjects with ASD and controls. The
Autism Diagnostic Observation Scale and Social Respon-
siveness Scale (SRS-2) scores that were used to evaluate
the severity of ASD were higher in individuals with ASD
compared to those in controls, as expected.
To profile miRNA expression, we performed miRNA
microarray analysis as previously described [6]. High-
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Fig. 1 (See legend on next page.)
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quality RNA with an average RNA integrity number
(RIN) of 8.7 was used; quality did not significantly differ
between the two groups (Additional file 1: Table S1).
We identified 18 miRNAs (2 up-regulated and 16 down-
regulated) that exhibited significant change between
ASD and control groups (Fig. 1b and Additional file 2:
Table S2). In particular, miR-6126, miR-3156-5p, miR-
1227-5p, miR-6780a-5p, and miR-328-3p were most sig-
nificantly dysregulated in ASD. To assess the robustness
of our results, we applied differentially expressed miR-
NAs that were identified by microarray analysis to the
Coarse Approximation Linear Function algorithm [7].
Upon analyses of 2000 random selections of subsets
representing 80% of individuals, miR-6126 was most fre-
quently selected (Fig. 1c). We subsequently confirmed
that miR-6126 was significantly down-regulated (p = 7.48E
− 3) in ASD using quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) (Fig. 1d). Together,
these results indicated that miR-6126 may serve as the
most promising indicator of ASD status in the blood from
subjects with high-functioning adult ASD.
To clarify relationships between the expression of
miR-6126 and clinical severity of ASD symptoms, we
performed correlation analysis. Notably, the expression
of miR-6126 was significantly negative correlated with
SRS-2 total score (r = − 0.35, p = 0.02) (Fig. 1e). In con-
trast, there was no significant correlation between the
expression of miR-6126 and IQ scores (full scale, verbal,
and performance) (Additional file 3: Table S3). These re-
sults suggested that miR-6126 expression is associated
with social severity of ASD, independent from IQ. Next,
to examine whether miR-6126 is expressed in brain, we
analyzed miR-6126 expression in a variety of normal hu-
man tissues. We found that miR-6126 was highly
enriched in brain tissue among human organs (Fig. 1f).
Furthermore, to investigate the biological significance of
miR-6126, we searched predicted target genes using the
miRWalk 2.0 database [8] (Additional file 4: Table S4).
The obtained 1167 predicted target genes were subjected
to Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment ana-
lysis. Notably, our results indicated that target genes of
miR-6126 are significantly related to axons, neuron guid-
ance, and oxytocin signaling pathways (Fig. 1g and
Additional file 5: Table S5). We also found that miR-
6126 targets were significantly enriched for ASD-related
genes (Fig. 1g). Notably, target genes included represen-
tative ASD-related genes such as ANK3, CACNA2D1,
NRXN3, and PCDH9. Taken together, these findings
provide new insight into the potential association of
miR-6126 with social deficits in ASD.
Multiple miRNAs have been proposed as potential bio-
markers for children with ASD; however, many results are
not consistent across studies [5]. The reasons may be due
to different factors such as tissue, RNA quality, and medi-
cation status. Accordingly, we carefully controlled poten-
tial factors including only high-quality RNA and
individuals not receiving medication. To date, miR-6126
has been reported to be associated with non-psychiatric
diseases, such as ovarian cancer, diabetic nephropathy,
and immune thrombocytopenic purpura [9–11]. Never-
theless, the effects of miR-6126 toward ASD and brain
function remain unknown. In addition to the brain, we
found that miR-6126 was expressed in the heart to a mod-
erate extent (Fig. 1f). Recent studies have suggested lower
heart rate variability in ASD compared to controls [12].
Although further investigations are warranted, our results
may provide clues for the underlying mechanisms of po-
tential cardiovascular risks in ASD. Notably, miR-6126 is
located on 16p13.3, within a copy number variation region
significantly associated with ASD that includes RBFOX1,
CREBBP, TRAF7, and TSC2 genes [13]. Conversely, al-
though several studies have examined miRNA expression
in adult ASD postmortem brains [14–16], none have re-
ported altered expression of miR-6126. This may be due
to these studies being likely based on older versions of
miRBase database that did not include information re-
garding miR-6126.
Several limitations to our findings should be carefully
considered. First, the sample size is relatively small. Sec-
ond, patients consisted of only Japanese individuals from
a single university hospital. Third, several factors might
impact miRNA assays. Although we confirmed that the
differences in estimated blood cell compositions among
groups were not significant (Additional file 6: Figure S1),
we could not control for the influence of sample collec-
tion time or fasting state. Finally, in this study, the target
genes of miR-6126 were predicted based on a database
(See figure on previous page.)
Fig. 1 miRNA expression profiles in blood from adults with high-functioning ASD and controls. a Flow chart of the study design. b Differential
miRNA expression profiles determined using microarray. Red dots indicate miRNAs with p-values < 0.01 and |fold change| > 1.5. c Frequency of
miRNA selection was calculated using a greedy algorithm. A total of 2000 selections using random 80% subsets of both ASD and controls were
run. The eight most frequently selected miRNAs are shown. d Expression level of miR-6126 by qRT–PCR. U6 snRNA was used as an internal
control. Data are presented as the upper and lower quantiles and range (box). *p < 0.01 e Correlation between miR-6126 expression level and
SRS-2 total score. Spearman’s correlation coefficients are shown. f Expression level of miR-6126 across human tissues. U6 snRNA was used as an
internal control. Relative expression was quantified using the ddCt method. g GO/KEGG pathway, and ASD-related gene enrichment analyses of
target genes of miR-6126. Red line indicates p-values < 0.05
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and were subsequently applied for enrichment analysis.
To validate these results, an experimental approach will
be needed to identify actual targets of miR-6126.
To our knowledge, this is the first pilot study demon-
strating the miRNA expression profile of peripheral
blood from adults with high-functioning ASD. The iden-
tified miR-6126 was down-regulated in ASD, correlated
with the severity of social deficits, and had predicted tar-
get genes associated with neurons and oxytocin signaling
pathways. These findings may provide new insights
regarding the molecular clues for recognizing high-
functioning ASD. To confirm our findings, further stud-
ies with more samples and experimental validation are
required.
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